Seeking Alpha

Seeking Alpha Portfolio App for iPad

678 people get PBTH articles and Market Currents by email alert.

Get email alerts on PBTH »

PBTH

PROLOR Biotech Inc

5/24/2013, 9:46 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, April 24, 9:11 AM Premarket gainers: BKI +26%. PBTH +11%. LL +7%. PSTI +5%.
Losers: VOCS -31%. UIS -20%. EW -19%. RES -13%. AWAY -9%. SCON -9%. JNPR -7%. SVU -7%. PNRA -6%. CREE -6%. Comment! [On the Move]
Wednesday, April 24, 9:08 AM Prolor Biotech (PBTH), will be acquired by OPKO Health (OPK) in an all-stock deal worth $480M. PBTH shareholders will get 0.9551 shares of OPK for every share of PBTH they own, equating to $7 per share as of Tuesday's closing prices. PBTH +10.65% premarket. (Previously: strategic alternative evaluation boosts Prolor) 2 Comments [M&A, On the Move]
Thursday, April 11, 12:49 PM Midday top 10 gainers: ACAD +55%. RNIN +26%. RAD +18%. ZUMZ +15%. MEA +13%. BIOL +12%. MGT +12%. PBTH +12%. MPAC +11%. TVL +11%.
Midday top 10 losers: LEDS -17%. FTNT -14%. ROYL -14%. NTIC -16%. HXM -11%. CREG -11%. PRMW -10%. GNVC -10%. SGYP -10%. OCZ -10%. Comment! [On the Move]
Thursday, April 11, 11:02 AM Prolor Biotech (PBTH +8.2%) hires Jefferies Group to evaluate strategic alternatives. An unnamed source says the company has drawn interest from big pharma over the past 12 months, but notes PBTH has not decided to sell itself. SA contributor Daniel Lauchheimer's article suggesting the stock has "unlimited upside" looks prescient. (See also: PBTH gets orphan drug designation) Comment! [Healthcare, On the Move]
Wednesday, February 13, 11:14 AM Prolor Biotech (PBTH +4.2%) gets a boost from an orphan drug designation for hGH-CTP, a long-acting treatment for growth hormone deficiency from the European Commission and the European Medicines Agency. The approval marks the first time a growth hormone has received any such a designation in Europe, and once launced, the drug will receive 10 years of marketing exclusivity in Europe. Comment! [Healthcare, On the Move]
Wednesday, October 3, 2012, 9:27 AM Prolor Biotech (PBTH) +8.3% premarket after receiving a notice of allowance from the U.S. patent office for a new patent application covering its long-acting CTP-enhanced human growth hormone. The patent gives PBTH additional intellectual property protection covering methods for the induction of growth in growth hormone deficient patients. Comment! [Healthcare, On the Move]
Friday, May 11, 2012, 9:15 AM Premarket gainers: ARNA +93%. GV +45.5%. ATHX +15%. AVG +12%. ZOOM +9%. MDR +9%. SOL +8%. NVDA +8%.
Losers: RNDY -11%. PBTH -11%. DAR -9%. JPM -8.5%. SNE -8%. Comment! [On the Move]
Tuesday, April 17, 2012, 9:56 AM Prolor Biotech (PBTH +4.9%) reports positive pre-clinical results from an animal study for its obesity and Type II diabetes drug candidate MOD-6030. When administered once a week over 30 days, PBTH says the treatment produced an average weight loss of 28% and a 19% reduction in blood glucose levels. Comment! [Healthcare, On the Move]
Wednesday, January 18, 2012, 8:19 AM PROLOR Biotech (PBTH) announces that it achieved positive top-line results from a study of its human growth hormone tested in a Phase II clinical study. The results indicate the firm's drug may be able to achieve the same results as currently marketed treatments with fewer injections required. Shares +3.8% premarket. Comment! [On the Move, Healthcare]
Tuesday, January 17, 2012, 10:41 AM Prolor Biotech (PBTH +11.1%) follows up last week's strong gains with a double-digit move up. M.E. Garza attributes the buying to M&A chatter emerging out of a major healthcare conference last week in San Francisco on the strength of the firm's promising drug pipeline. Comment! [On the Move, Healthcare]
Wednesday, July 13, 2011, 10:57 AM PROLOR Biotech (PBTH) pops today, +11.3% to $5.61, after yesterday's initiation of coverage by Morgan Joseph at Buy with a target of $16. Also this week, Summer Street initiated coverage with a target of $8. The company develops therapeutic proteins and has full Phase II trial results ahead. Comment! [Healthcare, On the Move]